Table 2 Disease and demographic characteristics of study cohort (BA21, max n = 75)

Maximum n

18

22

21

14

Age at death, y

82.8 (1.2)

82.4 (1.0)

83.1 (1.6)

85.6 (1.5)

0.41

Female, %

9 (50.0)

11 (50.0)

11 (52.4)

8 (57.1)

0.98

Post-mortem interval^a, h

41.5 (5.7)

37.3 (3.6)

44.6 (6.2)

39.0 (6.5)

0.78

Tissue pH

6.4 (0.1)

6.5 (0.1)

6.2 (0.1)

6.4 (0.1)

0.11

MMSE decline per year^b

NA

2.3 (0.3)

3.0 (0.5)

4.0 (1.2)

0.30

Predeath MMSE^c

NA

10.9 (8.2)

12.2 (5.1)

8.4 (7.9)

0.52

Duration of dementia^d, y

NA

3.7 (0.6)

6.4 (0.9)^†

9.7 (0.8)^†

< 0.001

Duration of parkinsonism^e, y

NA

12.9 (1.3)

2.9 (0.7)

NA

< 0.001

Braak stage^f, n

0–II

13

15

4

0

NA

III–IV

0

6

8

2

NA

V–VI

0

1

9

11

NA

NP score^g

0.45 (0.2)

0.63 (0.1)

2.10 (0.2)*^†

2.92 (0.1)*^†

< 0.001

NFT score^h

0.09 (0.1)

0.37 (0.1)

1.40 (0.2)*^†

2.83 (0.2)*^†‡

< 0.001

LB scroreⁱ

0

0.89 (0.2)*

1.75 (0.3)*

0.25 (0.1)^‡

< 0.001